{
    "id": "6ef83e79-8d72-4714-9642-ef42ce31f54d",
    "indications": {
        "text": "wellbutrin sr ( bupropion hydrochloride ) indicated treatment major depressive disorder ( mdd ) , defined diagnostic statistical manual ( dsm ) . efficacy bupropion treatment major depressive episode established two 4-week controlled inpatient trials one 6-week controlled outpatient trial adult subjects mdd [ ( 14 ) ] . efficacy wellbutrin sr maintaining antidepressant response 44 weeks following 8 weeks acute treatment demonstrated placebo\u2011controlled trial [ ( 14 ) ] .",
        "doid_entities": [
            {
                "text": "major depressive disorder (DOID:1470)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1470"
            },
            {
                "text": "depressive disorder (DOID:1596)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1596"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 starting dose : 150 mg/day . ( 2.1 ) \u2022 general : increase dose gradually reduce seizure risk . ( 2.1 , 5.3 ) \u2022 3 days , may increase dose 300 mg/day , given 150 mg twice daily interval least 8 hours . ( 2.1 ) \u2022 usual target dose : 300 mg/day 150 mg twice daily . ( 2.1 ) \u2022 maximum dose : 400 mg/day , given 200 mg twice daily , patients responding 300 mg/day . ( 2.1 ) \u2022 periodically reassess dose need maintenance treatment . ( 2.1 ) \u2022 moderate severe hepatic impairment : 100 mg daily 150 mg every day . ( 2.2 , 8.7 ) \u2022 mild hepatic impairment : consider reducing dose and/or frequency dosing . ( 2.2 , 8.7 ) \u2022 renal impairment : consider reducing dose and/or frequency . ( 2.3 , 8.6 )",
        "doid_entities": [],
        "orphanet_entities": [
            {
                "disease": "severe hepatic impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            }
        ]
    },
    "warningsAndPrecautions": "wellbutrin sr sustained\u2011release tablets , 100 mg bupropion hydrochloride , blue , round , biconvex , film\u2011coated tablets printed \u201c wellbutrin sr 100 \u201d bottles 60 ( ndc 0173-0947-55 ) tablets . wellbutrin sr sustained\u2011release tablets , 150 mg bupropion hydrochloride , purple , round , biconvex , film\u2011coated tablets printed \u201c wellbutrin sr 150 \u201d bottles 60 ( ndc 0173-0135-55 ) tablets . wellbutrin sr sustained\u2011release tablets , 200 mg bupropion hydrochloride , light pink , round , biconvex , film\u2011coated tablets printed \u201c wellbutrin sr 200 \u201d bottles 60 ( ndc 0173-0722-00 ) tablets . store room temperature , 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] . protect light moisture .",
    "adverseReactions": "\u2022wellbutrin sr contraindicated patients seizure disorder . \u2022wellbutrin sr contraindicated patients current prior diagnosis bulimia anorexia nervosa higher incidence seizures observed patients treated immediate\u2011release formulation bupropion [ ( 5.3 ) ] . \u2022wellbutrin sr contraindicated patients undergoing abrupt discontinuation alcohol , benzodiazepines , barbiturates , antiepileptic drugs [ ( 5.3 ) , ( 7.3 ) ] . \u2022the maois ( intended treat psychiatric disorders ) concomitantly wellbutrin sr within 14 days discontinuing treatment wellbutrin sr contraindicated . increased risk hypertensive wellbutrin sr used concomitantly maois . wellbutrin sr within 14 days discontinuing treatment maoi also contraindicated . starting wellbutrin sr patient treated reversible maois linezolid intravenous methylene blue contraindicated [ ( 2.4 , 2.5 ) , ( 5.4 ) , ( 7.6 ) ] . \u2022wellbutrin sr contraindicated patients known hypersensitivity bupropion ingredients wellbutrin sr. anaphylactoid/anaphylactic stevens-johnson syndrome reported [ ( 5.8 ) ] .",
    "ingredients": [
        {
            "name": "BUPROPION HYDROCHLORIDE",
            "code": "ZG7E5POY8O",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_3220"
        },
        {
            "name": "CARNAUBA WAX",
            "code": "R12CBM0EIZ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_73702"
        },
        {
            "name": "CYSTEINE HYDROCHLORIDE",
            "code": "ZT934N0X4W",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15356"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53426"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "bupropion hydrochloride",
            "code": "ZG7E5POY8O",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_3220"
        }
    ],
    "organization": "GlaxoSmithKline LLC",
    "name": "WELLBUTRIN",
    "effectiveTime": "20240422",
    "indications_original": "WELLBUTRIN\u00a0SR (bupropion hydrochloride) is indicated for the treatment of major depressive disorder (MDD), as defined by the Diagnostic and Statistical Manual (DSM).\n                  The efficacy of bupropion in the treatment of a major depressive episode was established in two 4-week controlled inpatient trials and one 6-week controlled outpatient trial of adult subjects with MDD [see Clinical Studies (14)].\n                  The efficacy of WELLBUTRIN\u00a0SR in maintaining an antidepressant response for up to 44\u00a0weeks following 8\u00a0weeks of acute treatment was demonstrated in a placebo\u2011controlled trial [see Clinical Studies (14)].",
    "contraindications_original": "\u2022 Starting dose: 150 mg/day. ( 2.1 ) \u2022 General: Increase dose gradually to reduce seizure risk. ( 2.1 , 5.3 ) \u2022 After 3 days, may increase the dose to 300 mg/day, given as 150 mg twice daily at an interval of at least 8 hours. ( 2.1 ) \u2022 Usual target dose: 300 mg/day as 150 mg twice daily. ( 2.1 ) \u2022 Maximum dose: 400 mg/day, given as 200 mg twice daily, for patients not responding to 300 mg/day. ( 2.1 ) \u2022 Periodically reassess the dose and need for maintenance treatment. ( 2.1 ) \u2022 Moderate to severe hepatic impairment: 100 mg daily or 150 mg every other day. ( 2.2 , 8.7 ) \u2022 Mild hepatic impairment: Consider reducing the dose and/or frequency of dosing. ( 2.2 , 8.7 ) \u2022 Renal impairment: Consider reducing the dose and/or frequency. ( 2.3 , 8.6 )",
    "warningsAndPrecautions_original": "WELLBUTRIN\u00a0SR sustained\u2011release tablets, 100\u00a0mg of bupropion hydrochloride, are blue, round, biconvex, film\u2011coated tablets printed with \u201cWELLBUTRIN\u00a0SR\u00a0100\u201d in bottles of 60 (NDC 0173-0947-55) tablets.\n                  WELLBUTRIN\u00a0SR sustained\u2011release tablets, 150\u00a0mg of bupropion hydrochloride, are purple, round, biconvex, film\u2011coated tablets printed with \u201cWELLBUTRIN\u00a0SR\u00a0150\u201d in bottles of 60 (NDC 0173-0135-55) tablets.\n                  WELLBUTRIN\u00a0SR sustained\u2011release tablets, 200\u00a0mg of bupropion hydrochloride, are light pink, round, biconvex, film\u2011coated tablets printed with \u201cWELLBUTRIN SR 200\u201d in bottles of 60 (NDC 0173-0722-00) tablets.\n                  Store at room temperature, 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted between 15\u00b0C and 30\u00b0C (59\u00b0F and 86\u00b0F) [see USP Controlled Room Temperature]. Protect from light and moisture.",
    "adverseReactions_original": "\u2022WELLBUTRIN SR is contraindicated in patients with a seizure disorder.\n                     \n                        \u2022WELLBUTRIN SR is contraindicated in patients with a current or prior diagnosis of bulimia or anorexia nervosa as a higher incidence of seizures was observed in such patients treated with the immediate\u2011release formulation of bupropion [see Warnings and Precautions (5.3)].\n                     \n                     \n                        \u2022WELLBUTRIN SR is contraindicated in patients undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs [see Warnings and Precautions (5.3), Drug Interactions (7.3)].\n                     \n                        \u2022The use of MAOIs (intended to treat psychiatric disorders) concomitantly with WELLBUTRIN SR or within 14 days of discontinuing treatment with WELLBUTRIN SR is contraindicated. There is an increased risk of hypertensive reactions when WELLBUTRIN SR is used concomitantly with MAOIs. The use of WELLBUTRIN SR within 14 days of discontinuing treatment with an MAOI is also contraindicated. Starting WELLBUTRIN SR in a patient treated with reversible MAOIs such as linezolid or intravenous methylene blue is contraindicated [see Dosage and Administration (2.4, 2.5), Warnings and Precautions (5.4), Drug Interactions (7.6)].\n                     \n                        \u2022WELLBUTRIN SR is contraindicated in patients with known hypersensitivity to bupropion or other ingredients of WELLBUTRIN SR. Anaphylactoid/anaphylactic reactions and Stevens-Johnson syndrome have been reported [see Warnings and Precautions (5.8)].",
    "drug": [
        {
            "name": "WELLBUTRIN",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_3220"
        }
    ]
}